CN116249710A - 治疗性抗体 - Google Patents

治疗性抗体 Download PDF

Info

Publication number
CN116249710A
CN116249710A CN202180058009.6A CN202180058009A CN116249710A CN 116249710 A CN116249710 A CN 116249710A CN 202180058009 A CN202180058009 A CN 202180058009A CN 116249710 A CN116249710 A CN 116249710A
Authority
CN
China
Prior art keywords
sequence
seq
ser
antibody
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180058009.6A
Other languages
English (en)
Chinese (zh)
Inventor
艾伦·布拉德利
安德鲁·詹姆斯·汤普森
丹尼尔·约翰·波兰德
王珏璇
罗伯托·班迪耶拉
史蒂夫·霍尔姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pete Maidi Co ltd
Original Assignee
Pete Maidi Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pete Maidi Co ltd filed Critical Pete Maidi Co ltd
Publication of CN116249710A publication Critical patent/CN116249710A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180058009.6A 2020-08-07 2021-08-06 治疗性抗体 Pending CN116249710A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2012331.1A GB202012331D0 (en) 2020-08-07 2020-08-07 Therapeutic antibodies
GB2012331.1 2020-08-07
PCT/GB2021/052043 WO2022029447A1 (en) 2020-08-07 2021-08-06 Therapeutic antibodies

Publications (1)

Publication Number Publication Date
CN116249710A true CN116249710A (zh) 2023-06-09

Family

ID=72520053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180058009.6A Pending CN116249710A (zh) 2020-08-07 2021-08-06 治疗性抗体

Country Status (8)

Country Link
US (1) US20230272097A1 (enExample)
EP (1) EP4192867A1 (enExample)
JP (1) JP2023540444A (enExample)
CN (1) CN116249710A (enExample)
AU (1) AU2021319941A1 (enExample)
CA (1) CA3186391A1 (enExample)
GB (1) GB202012331D0 (enExample)
WO (1) WO2022029447A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US20220332837A1 (en) * 2021-04-08 2022-10-20 Colorado State University Research Foundation Methods and compositions for ox40 activation in treatment of canine cancer
IL314314A (en) * 2022-02-09 2024-09-01 Petmedix Ltd Therapeutic antibodies
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
AU2023417626A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (en) 2023-01-20 2024-07-25 Invetx, Inc. Bispecific binding agents for use in companion animals
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7812133B2 (en) * 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2013221502C1 (en) * 2012-02-14 2018-03-01 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
GB2561352B (en) 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
KR20250026872A (ko) 2018-03-16 2025-02-25 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
GB2578867A (en) 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules

Also Published As

Publication number Publication date
AU2021319941A1 (en) 2023-02-16
CA3186391A1 (en) 2022-02-10
GB202012331D0 (en) 2020-09-23
WO2022029447A1 (en) 2022-02-10
US20230272097A1 (en) 2023-08-31
JP2023540444A (ja) 2023-09-25
EP4192867A1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
US20230272097A1 (en) Therapeutic antibodies
JP7061235B2 (ja) 抗ｃｌｄ１８ａ２ナノ抗体及びその応用
TWI779479B (zh) 抗原結合分子類和使用彼等之方法
JP2022507487A (ja) Ｃｄ２５抗体
KR20180132751A (ko) Bcma 결합 분자 및 그의 사용 방법
TWI787594B (zh) 抗原結合分子和使用彼之方法
US20240150460A1 (en) Anti-nkp30 antibody and application thereof
WO2022007543A1 (zh) 一种抗fgl1抗体及其应用
CN113621065B (zh) 靶向4-1bb的全人源抗体及其制备方法和应用
US20250340659A1 (en) Therapeutic antibodies
JP2025534787A (ja) 抗ヒトインターロイキン３６受容体モノクローナル抗体及びその使用
TWI698643B (zh) 用於檢測米田堡血型抗原的抗體及其片段、試劑盒及方法
CN118715244A (zh) 治疗性抗体
CN114616245B (zh) 一种抗cd38的抗体及其用途
US11274161B2 (en) Monoclonal antibodies that specifically recognize canine DLA-DR antigen and their uses
CN121108346B (zh) 抗ly6g6d单域抗体及其制备方法和用途
JP7844430B2 (ja) 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体
CN114075284B (zh) Cd47结合分子及其用途
US20260035484A1 (en) Isolated antigen binding protein and use thereof
CN120842422A (zh) 一种抗CD30和CD16a的双特异性抗体及其应用
CN117677637A (zh) 抗犬cd20抗体
TW202405013A (zh) 一種抗原結合蛋白及其應用
CN117529501A (zh) 针对抗cd79b抗体的抗独特型抗体
CN120693348A (zh) 人抗pd-l2抗体及其用途
CN118580351A (zh) Cd3特异性抗体及其制备方法和相关应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: United Kingdom

Address after: cambridge

Applicant after: Suzhou Service United Kingdom Limited

Address before: cambridge

Applicant before: Pete Maidi Co.,Ltd.

Country or region before: United Kingdom